{"id":"npc-02","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":{"chemblId":"CHEMBL2372276","moleculeType":"Protein","molecularWeight":"1363.59"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, NPC-02 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"NPC-02 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:24.750Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00212355","phase":"PHASE3","title":"Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2005-03","conditions":"Wilson's Disease","enrollment":37},{"nctId":"NCT02337569","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2015-01","conditions":"Zinc Deficiency","enrollment":57},{"nctId":"NCT02321865","phase":"PHASE3","title":"Dose Adjustment Study of NPC-02 in Patients With Zinc Deficiency","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2015-01-21","conditions":"Zinc Deficiency","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NPC-02","genericName":"NPC-02","companyName":"Nobelpharma","companyId":"nobelpharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NPC-02 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}